CKM syndrome is a relatively new framework adopted by the American Heart Association to describe what happens when metabolic dysfunction, chronic kidney disease, and cardiovascular disease become entangled in a self-reinforcing spiral. Obesity drives insulin resistance, insulin resistance promotes inflammation and vascular damage, declining kidney function accelerates hypertension and fluid overload, and the failing heart in turn worsens kidney perfusion. The syndrome is formally staged from 0 to 4, with stage 0 representing no risk factors and advanced stages reflecting established metabolic, renal, and cardiac pathology. Because the condition develops silently over decades, clinicians have long sought biomarkers that can flag patients on the trajectory toward advanced disease while intervention is still possible. Existing markers capture fragments of the picture — glycated hemoglobin reflects glucose control, estimated glomerular filtration rate reflects kidney function, and lipid panels reflect cholesterol metabolism — but none integrates the inflammatory and nutritional dimensions that underpin the entire syndrome.

That is precisely the gap the RAR index is designed to fill. Red blood cell distribution width, or RDW, is a standard parameter reported by every automated hematology analyzer; it quantifies the variability in the size of circulating red blood cells. Elevated RDW is a well-documented marker of systemic inflammation, oxidative stress, and disordered iron metabolism, and it has repeatedly been linked to worse outcomes in heart failure, coronary disease, and atrial fibrillation. Albumin, meanwhile, is the most abundant protein in blood plasma, synthesized by the liver, and serves as a sensitive barometer of nutritional status, liver synthetic capacity, and the systemic inflammatory response — inflammation suppresses albumin production and increases its leakage from the vascular compartment. Dividing RDW by albumin concentration therefore yields a composite measure in which a rising numerator signals inflammatory stress and a falling denominator signals nutritional decline, producing a single number that climbs as both pathologies worsen.

To test whether this composite index tracks CKM syndrome severity, the research team, led by investigators at Zhejiang University School of Medicine in Hangzhou, China, turned to two complementary population resources. The first was the National Health and Nutrition Examination Survey (NHANES), a continuous program of the US National Center for Health Statistics that combines standardized physical examinations with laboratory testing in a nationally representative sample; the team analyzed NHANES cycles from 1999 to 2018, encompassing 32,068 participants. The second was the UK Biobank, a prospective cohort of half a million British adults recruited between 2006 and 2010, from which 110,123 participants with the required baseline data were included. Together the two cohorts provided 142,191 individuals, allowing the researchers to test their hypotheses both cross-sectionally, in a snapshot of the population at a single time point, and longitudinally, by following participants forward in time to see who developed cardiovascular disease.

The analytical strategy was deliberately rigorous. Because CKM syndrome is staged rather than binary, the team used multinomial logistic regression to model the odds of belonging to each progressively more severe stage as RAR increased. For the longitudinal component, they applied multivariate Cox proportional hazards regression, the standard framework for time-to-event analysis, to estimate how baseline RAR predicted the future occurrence of cardiovascular disease overall and of specific endpoints including coronary heart disease, heart failure, atrial fibrillation, peripheral artery disease, and stroke. To probe the shape of the dose-response relationship, they employed restricted cubic splines, a flexible modeling technique that can reveal nonlinear patterns without imposing a rigid linear assumption. All models were adjusted for the standard battery of confounders — age, sex, body mass index, smoking status, hemoglobin A1c, high-density lipoprotein cholesterol, estimated glomerular filtration rate, and the urinary albumin-to-creatinine ratio among them — and the authors accounted for multiple testing using false discovery rate control.

The results were strikingly consistent across both cohorts. In the cross-sectional analyses, each standard deviation increase in RAR was associated with a 47 percent greater odds of advanced CKM stages in the NHANES population, with an odds ratio of 1.47 and a 95 percent confidence interval of 1.42 to 1.54. In the UK Biobank, the corresponding odds ratio was 1.23 with a confidence interval of 1.21 to 1.25 — a somewhat smaller but still highly significant effect, and one that all p-values below 0.001 render statistically robust. The difference in magnitude between the two cohorts is itself informative: NHANES captures a nationally representative sample with wide variation in metabolic health, whereas UK Biobank participants tend to be healthier than the general British population, a well-known phenomenon that typically attenuates risk estimates. That the association survived in both settings, and in both a cross-sectional and a longitudinal design, strengthens the case that RAR is genuinely tracking disease biology rather than some artifact of a single population or study design.

The longitudinal findings extend the story beyond staging into prediction. Elevated baseline RAR predicted an increased risk of incident cardiovascular disease overall, with a hazard ratio of 1.12 per standard deviation increase and a 95 percent confidence interval of 1.10 to 1.14. When the investigators broke cardiovascular disease down into its component diagnoses, the signal persisted across the board: coronary heart disease, heart failure, atrial fibrillation, peripheral artery disease, and stroke were all individually predicted by higher RAR, again with p-values below 0.001. Restricted cubic spline analysis indicated that the relationship between RAR and CKM stages held across the observed range of the index, supporting its use as a continuous risk variable rather than requiring an arbitrary cutoff. Notably, the association was strongest in CKM stages 2 and 3 — the transitional phases in which metabolic risk factors have crystallized into organ-level pathology but before overt cardiovascular events have occurred. This is exactly the window in which aggressive management of blood pressure, glucose, lipids, and kidney function can change the trajectory of the disease.

The biological plausibility of these findings rests on the convergence of two well-characterized pathways. Chronic low-grade inflammation is now recognized as a central driver of atherosclerosis, insulin resistance, and kidney fibrosis; inflammatory cytokines perturb erythropoiesis and iron homeostasis, widening the distribution of red cell sizes, while simultaneously suppressing hepatic albumin synthesis. Poor nutrition, another hallmark of advancing CKM syndrome, independently lowers albumin. An elevated RAR therefore functions as a readout of the inflammatory-nutritional axis that sits at the heart of the syndrome’s pathophysiology. The authors argue that this integrative quality is what gives RAR its stage-dependent behavior: as the syndrome progresses from isolated risk factors to multisystem organ involvement, both inflammation and nutritional compromise intensify, and the index rises in step.

For clinical practice, the appeal of RAR is practical as much as scientific. Both RDW and albumin are measured routinely in complete blood counts and metabolic panels, meaning the index can be calculated at no additional cost from data already sitting in the electronic health record. The study’s authors conclude that RAR serves as a robust, stage-dependent biomarker for higher CKM stages and cardiovascular incidence, with potential utility for risk stratification of CKM severity and for guiding early cardiovascular intervention strategies. They are careful to frame the work as associative rather than causative — an elevated RAR does not itself damage the heart or kidneys, but it may reveal the underlying inflammatory and metabolic fire that does. The study also carries the usual caveats of observational research: residual confounding cannot be excluded, NHANES and UK Biobank populations are predominantly of European and American ancestry, and the UK Biobank’s healthy-volunteer effect may limit generalizability to the sickest patients. Prospective validation in diverse cohorts and demonstration that RAR-guided management improves outcomes would be the necessary next steps before the index earns a place in formal guidelines.

Even so, the study adds momentum to a broader shift in cardiology and nephrology toward cheap, integrative biomarkers that capture multisystem risk. As the American Heart Association’s CKM staging framework spreads into routine care, tools that can assign patients to a stage quickly and inexpensively will be in growing demand. A ratio derived from two numbers that already appear on nearly every admission bloodwork — one measuring how unevenly a patient’s red blood cells are built, the other measuring how well their liver and nutrition are holding up against systemic disease — may prove to be exactly such a tool, flagging the silent progression of cardiovascular-kidney-metabolic syndrome years before the first heart attack or stroke makes it impossible to ignore.

Subject of Research: Association between the red blood cell distribution width to albumin ratio and cardiovascular-kidney-metabolic syndrome stages and cardiovascular disease risk

Article Title: Ratio of red blood cell distribution width to albumin concentration and risk of cardiovascular-kidney-metabolic syndrome stages

Article References: Zhou, X., Wu, S., Lu, Y., Zhu, S., Liu, C., Shen, J., Xiang, M., Wu, X., & Xie, Y. (2026). Ratio of red blood cell distribution width to albumin concentration and risk of cardiovascular-kidney-metabolic syndrome stages. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02595-2

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02595-2

Keywords: cardiovascular-kidney-metabolic syndrome, RAR index, red blood cell distribution width, albumin, biomarker, NHANES, UK Biobank, cardiovascular disease, chronic kidney disease, inflammation, risk stratification, metabolic syndrome

The answer, according to the study, is a qualified yes. Participants in the highest quarter of baseline RCII values had a 36 percent higher risk of developing cardiovascular disease during follow-up than those in the lowest quarter, after the researchers statistically accounted for a long list of confounders including age, sex, blood pressure, diabetes status, kidney function, smoking and body mass index. The hazard ratio was 1.36, with a 95 percent confidence interval of 1.11 to 1.67 and a P value of 0.003, meaning the association was unlikely to be a statistical fluke. When the team adjusted the analysis for high-sensitivity C-reactive protein itself—the inflammatory component baked into the index—the estimate actually strengthened slightly, rising to a hazard ratio of 1.41, which suggests the signal is not simply an artifact of measuring inflammation twice.

To understand why this matters, it helps to unpack the two ingredients. Remnant cholesterol is the cholesterol carried in triglyceride-rich lipoproteins, the partially degraded leftovers of very-low-density lipoproteins and chylomicrons that circulate after a meal. Unlike LDL cholesterol, which has dominated cardiovascular prevention for decades, remnant particles are small enough to slip into the arterial wall and are thought to be particularly adept at triggering the fatty plaques that underlie atherosclerosis. High-sensitivity C-reactive protein, meanwhile, is the blood’s most widely used barometer of systemic inflammation, and elevated levels have long been linked to cardiovascular events independently of cholesterol. By combining the two into a single index, the authors aimed to capture a dual burden: the metabolic insult of cholesterol-rich remnant particles and the inflammatory response they provoke.

The study drew its participants from the China Health and Retirement Longitudinal Study, known as CHARLS, a nationally representative survey of Chinese adults aged 45 and older that has become one of the most valuable resources for studying aging and chronic disease in the world’s most populous country. Of the 4,606 adults included in the baseline analysis, 791 went on to develop cardiovascular disease over a median follow-up of 7.0 years. The researchers classified everyone according to the cardiovascular-kidney-metabolic syndrome staging framework, a relatively new scheme promoted by the American Heart Association that ranges from stage 0, meaning no metabolic risk factors at all, through stages 1 to 3, which encompass excess body fat, metabolic risk factors such as hypertension and diabetes, and kidney disease. Crucially, the elevated RCII signal held across all of these stages, from the apparently healthy to the already at-risk.

One of the study’s more intriguing technical findings concerns the shape of the relationship. Using a statistical technique called restricted cubic splines, which allows the data to reveal curves rather than forcing them into straight lines, the researchers found that the association between baseline RCII and cardiovascular risk was nonlinear, with a P value for nonlinearity of 0.002. In practical terms, this means the risk does not climb steadily with each incremental rise in the index. Instead, the analysis suggests a threshold-like pattern in which risk accelerates at higher values of the index, a shape that could have implications for how such a marker might eventually be used in clinical screening, since it hints at a range above which the index becomes most informative.

But the study also delivers a sobering lesson in epidemiological humility. Because a single blood measurement at baseline might miss how a person’s cholesterol and inflammation levels fluctuate over the years, the team also calculated a cumulative RCII, averaging repeated measurements across survey waves. They then performed a landmark analysis, restarting the clock in 2015 and following only the 4,129 participants who were still free of cardiovascular disease at that point. Among these, 449 developed cardiovascular disease, and this time the association fell short of statistical significance: the highest versus lowest cumulative RCII quartile yielded a hazard ratio of 1.17, with a confidence interval of 0.89 to 1.54 that comfortably includes the null value of 1.0, and a P value of 0.275.

That discrepancy between the baseline and cumulative analyses is more than a statistical footnote; it is a window into how risk markers can behave differently depending on how they are measured. One plausible interpretation is that a single, sharply elevated measurement captures an acute or sustained metabolic-inflammatory state that is genuinely dangerous, whereas averaging values over time dilutes the signal, blending high-risk periods with calmer ones. Alternatively, the smaller number of events in the landmark cohort—449 versus 791—reduced the statistical power available to detect a real effect, so the cumulative result may reflect insufficient data rather than a truly absent association. The authors are careful to frame RCII as a candidate risk marker rather than a validated clinical tool, and the cumulative finding underscores why such caution is warranted.

The researchers also probed whether the association varied across subgroups defined by age, sex, hypertension, diabetes and other characteristics, and found no significant interactions, meaning the elevated index appeared to carry similar prognostic weight across these strata. That consistency is encouraging for a potential biomarker, because a measure whose meaning shifts dramatically between patient groups is far harder to deploy in practice. It also aligns with the broader conceptual appeal of the cardiovascular-kidney-metabolic framework itself, which was designed to encourage clinicians to see heart disease, kidney dysfunction and metabolic disorders as an interconnected continuum rather than separate silos. A marker that integrates a metabolic lipid abnormality with inflammation fits naturally into that unified view of risk.

Several caveats temper the excitement. This is an observational study, so it can demonstrate association but not prove that a high RCII causes cardiovascular events; it remains possible that unmeasured factors drive both the index and the outcomes. The cohort consists of Chinese adults aged 45 and older, and whether the findings generalize to younger populations or to other ethnic groups is unknown. The index itself is a derived composite, and its exact formulation would need standardization and external validation in independent cohorts before it could inform screening guidelines or treatment decisions. And although remnant cholesterol can be estimated from standard lipid panels using the Friedewald-style calculation, its accuracy depends on fasting status and triglyceride levels, adding practical wrinkles to any future clinical rollout.

Still, the study adds a compelling piece to a rapidly evolving puzzle. Cardiovascular disease remains the leading cause of death worldwide, and a substantial share of events occurs in people whose conventional risk factors appear unremarkable, fueling the search for markers that reveal hidden risk. Remnant cholesterol has surged in scientific prominence in recent years as genetic and mechanistic studies have implicated it in atherosclerosis independently of LDL, and inflammation has been validated as a therapeutic target by landmark trials of anti-inflammatory drugs. An index that marries the two is a logical next step, and the finding that it predicts incident cardiovascular disease across cardiovascular-kidney-metabolic stages 0 through 3, with a nonlinear dose-response and robustness across subgroups, marks it as a candidate worth watching. If future studies confirm these results and clarify the ambiguous cumulative signal, the humble arithmetic of combining two routine blood tests could one day help clinicians catch cardiovascular danger years before the first symptom appears.

Subject of Research: Association between the remnant cholesterol inflammatory index and incident cardiovascular disease risk across cardiovascular-kidney-metabolic syndrome stages

Article Title: Association of remnant cholesterol inflammatory index and cardiovascular risk among individuals across cardiovascular-kidney-metabolic syndrome stages 0–3: a nationwide prospective cohort study

Article References: Hu, W., Zou, H., & Li, P. (2026). Association of remnant cholesterol inflammatory index and cardiovascular risk among individuals across cardiovascular-kidney-metabolic syndrome stages 0–3: a nationwide prospective cohort study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02590-7

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02590-7

Keywords: remnant cholesterol, inflammation, cardiovascular disease, cardiovascular-kidney-metabolic syndrome, C-reactive protein, biomarker, cohort study, CHARLS, atherosclerosis, risk prediction, metabolic syndrome, epidemiology

The study, led by Yi Zhang and AnGe Liu of Capital Medical University’s Beijing Chao-Yang Hospital together with colleagues, drew on data from the China Health and Retirement Longitudinal Study, known as CHARLS. This nationally representative cohort follows adults aged 45 and older across China, and the research team focused on 4,219 participants classified within stages 0 to 3 of the cardiovascular-kidney-metabolic, or CKM, syndrome. This staging framework, promoted by the American Heart Association, recognizes that obesity, metabolic dysfunction, chronic kidney disease, and cardiovascular disease form an interconnected continuum rather than separate conditions. Stage 0 represents no detectable risk factors, while stage 3 involves subclinical cardiovascular disease or high-risk metabolic states, meaning the study population had not yet reached overt clinical cardiovascular events.

To quantify frailty, the investigators constructed a 32-item frailty index, a tool rooted in the cumulative deficit model of aging developed by geriatricians Kenneth Rockwood and Arnold Mitnitski. Rather than defining frailty through a handful of physical measures such as grip strength or walking speed, the frailty index aggregates deficits across many domains, including symptoms, chronic conditions, functional limitations, and cognitive measures. Each participant’s index score represents the proportion of deficits present, so a score of 0.25 means roughly a quarter of the measured health items are impaired. Participants were classified at baseline as robust, pre-frail, or frail depending on their index values.

The central innovation of the study, however, was its longitudinal design. Using frailty index measurements from four waves spanning 2011 to 2018, the researchers applied latent class growth modeling, a statistical technique that identifies hidden subgroups of people who share similar trajectories over time. Three distinct patterns emerged: a low-stable trajectory in which frailty remained minimal, a moderate-gradual increase trajectory showing steady deficit accumulation, and a high-rapid rise trajectory characterized by both elevated starting frailty and accelerating deterioration. This approach captures something a single snapshot cannot: the velocity of biological decline.

During follow-up, 541 participants developed cardiovascular disease. After adjusting for a comprehensive set of confounders, the differences between trajectory groups were striking. Compared with the low-stable group, those on the moderate-gradual increase trajectory had 87 percent higher odds of cardiovascular disease, with an odds ratio of 1.87 and a 95 percent confidence interval of 1.51 to 2.32. The high-rapid rise group fared far worse, with odds ratios reaching 3.52, or a confidence interval of 2.55 to 4.87, both statistically significant at P less than 0.001. In other words, people whose frailty was climbing quickly faced more than three and a half times the odds of a cardiovascular event compared with those whose deficit burden stayed low and flat.

The association was even more dramatic for stroke. Among participants on the high-rapid rise trajectory, the odds of stroke occurrence reached an odds ratio of 4.98, with a confidence interval of 3.01 to 8.24. This near fivefold elevation suggests that accelerating frailty is particularly informative about cerebrovascular risk, a finding consistent with growing evidence linking frailty to cerebrovascular disease mechanisms. The frailty index captures not only vascular risk factors but also inflammation, muscle wasting, and declining physiological reserve, all of which may converge to make the brain’s blood supply especially vulnerable.

Because observational studies of trajectories can be vulnerable to reverse causation, meaning that subclinical disease might itself drive frailty upward, the team performed two sensitivity analyses designed to strengthen causal interpretation. In a wave 4 fixed-interval landmark analysis, they examined events recorded at wave 5 among people still event-free at wave 4. In a wave 3 landmark Cox analysis, they tracked incident events at waves 4 and 5, and crucially, additionally adjusted for baseline frailty index. Both landmark analyses reproduced the primary association pattern, and in the wave 3 Cox analysis the links with total cardiovascular disease and stroke persisted even after accounting for starting frailty levels. This indicates that the trajectory itself, the rate and pattern of change, carries prognostic information beyond a single baseline measurement.

The study also confirmed that baseline frailty status matters on its own. In multivariable-adjusted Cox models, pre-frail participants had a 61 percent higher hazard of incident cardiovascular disease compared with robust participants, with a hazard ratio of 1.61 and a confidence interval of 1.33 to 1.95, while frail participants showed a hazard ratio of 1.63, with a confidence interval of 1.23 to 2.17. Interestingly, the hazard for pre-frail and frail groups was nearly identical, hinting that even early deficit accumulation, well before overt frailty, already elevates cardiovascular risk. This challenges the common clinical habit of waiting until frailty is unmistakable before acting.

What might explain the biology behind these numbers? Frailty is increasingly understood as a state of diminished resilience driven by chronic low-grade inflammation, a phenomenon sometimes called inflammaging. Elevated circulating inflammatory markers such as interleukin-6 and C-reactive protein promote atherosclerosis, endothelial dysfunction, and thrombosis while simultaneously eroding muscle mass and cognitive function. Within the cardiovascular-kidney-metabolic framework, these processes are amplified: metabolic syndrome accelerates vascular damage, declining kidney function worsens fluid and mineral balance, and the resulting cardiac stress feeds back into further functional decline. A rapidly rising frailty index may therefore be an integrated readout of this vicious cycle, capturing the cumulative toll across organ systems that individual biomarkers miss.

The practical implications are considerable. Cardiovascular disease remains the leading cause of death globally, and risk prediction models that incorporate cardiovascular-kidney-metabolic health have been endorsed by the American Heart Association, yet they rely largely on conventional measures such as blood pressure, cholesterol, and glucose. The new findings suggest that serial frailty index assessment, which can be computed from routine clinical and self-reported data, could complement these models by flagging people whose health is deteriorating faster than their risk factors alone would predict. For clinicians managing the vast population of adults in early CKM stages, the message is that a single frailty assessment is a starting point, not a verdict. Repeated measurement can identify persistent or accelerating deficit accumulation that may warrant closer longitudinal monitoring, earlier intervention, and potentially targeted prevention before the first heart attack or stroke occurs. As populations age worldwide, tracking the speed of biological aging may prove as important as tracking the numbers on a lipid panel.

Subject of Research: Association between longitudinal frailty index trajectories and cardiovascular disease risk in adults with early cardiovascular-kidney-metabolic syndrome

Article Title: Frailty trajectories and cardiovascular disease in adults with CKM stages 0–3

Article References: Zhang, Y., Liu, A., Shi, C., Xu, Y., Yang, R., & An, Z. (2026). Frailty trajectories and cardiovascular disease in adults with CKM stages 0–3. GeroScience. https://doi.org/10.1007/s11357-026-02559-3

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02559-3

Keywords: frailty, frailty index, cardiovascular disease, cardiovascular-kidney-metabolic syndrome, stroke, CHARLS, longitudinal trajectories, latent class growth modeling, aging, risk prediction, GeroScience, inflammaging

The research, led by Xinru Peng, Wenli Li, Yujiong Chen and Guowei Li together with colleagues including Lu Qi, Ai Zhao, Zebing Ye, Gregory Y. H. Lip and Miaoguan Peng, took advantage of an unusually powerful design: two parallel analyses of large prospective cohorts, one in the United Kingdom and one in China. The team drew on 352,297 participants from the UK Biobank and 7,610 participants from the China Health and Retirement Longitudinal Study, known as CHARLS. In both datasets, participants were classified into stages of CKM syndrome using definitions aligned with the American Heart Association’s staging framework, which ranges from stage 0, indicating no detectable risk factors, through stages 1 to 3, reflecting progressively more advanced metabolic, kidney, and vascular abnormalities without established clinical cardiovascular disease.

Classifying CKM stage required an extensive set of measurements. The researchers used body mass index, waist circumference, blood pressure, glycosylated hemoglobin, high-density and low-density lipoprotein cholesterol, triglycerides, and estimated glomerular filtration rate, alongside documented diagnoses such as hypertension, diabetes, and chronic kidney disease. In the UK Biobank, participants could be assigned to any of stages 0 through 3; in CHARLS, the available data allowed classification into combined stages 0 to 1, stage 2, or stage 3. The outcome of interest was incident cardiovascular disease during follow-up, encompassing events such as myocardial infarction, coronary heart disease, and stroke ascertained through hospital and mortality records. Multivariable Cox proportional hazards models, adjusted for a wide range of demographic, clinical, socioeconomic, and behavioral covariates, were used to estimate how much risk differed between males and females at each stage.

The headline numbers from the two cohorts point in opposite directions. In the UK Biobank, 32,268 participants, or 9.16 percent of the sample, developed cardiovascular disease during follow-up. That burden fell unequally by sex: 19,421 males, representing 12.37 percent of males in the cohort, experienced an event, compared with 12,847 females, or 6.58 percent of females. After full statistical adjustment, males had a 79 percent higher risk of cardiovascular disease than females, with a hazard ratio of 1.79 and a 95 percent confidence interval spanning 1.75 to 1.84. Strikingly, this pattern of elevated male risk persisted across every CKM stage from 0 through 3, suggesting that the male disadvantage in the UK population is not confined to a particular point along the disease continuum but permeates the entire preclinical spectrum.

CHARLS told the reverse story. Among 7,610 Chinese participants, 1,379 cardiovascular events occurred, an incident rate of 18.12 percent that reflects the older age structure of the cohort and shorter follow-up intervals typical of repeated survey-based studies. Here it was females who fared worse: 800 females, or 20.06 percent, experienced an incident cardiovascular event, compared with 579 males, or 15.99 percent. In fully adjusted models, males had a 26 percent lower risk of cardiovascular disease than females, with a hazard ratio of 0.74 and a 95 percent confidence interval of 0.62 to 0.87. The direction of this association held across CKM stages 0-1, 2, and 3, although the estimate at stage 3 was imprecise and did not reach statistical significance, a limitation the authors attribute to the smaller number of participants in that stratum.

What could produce such a dramatic geographic reversal? The researchers probed this question through mediation-style analyses examining whether socioeconomic status and lifestyle behaviors could account for part of the observed sex differences, and in both cohorts these factors partially explained the associations. In the UK Biobank, the excess male risk was partly attributable to unfavorable patterns in socioeconomic circumstances and health behaviors such as smoking, diet, physical activity, and alcohol consumption. In CHARLS, the elevated risk observed among females was likewise partly attenuated when socioeconomic and lifestyle variables were taken into account. These findings imply that sex differences in cardiovascular risk are not purely biological; they are woven into the social and behavioral fabric of each population, from occupational exposures and income gradients to gendered patterns of smoking, caregiving, and healthcare access.

The methodological scaffolding behind these conclusions was deliberately robust. The team verified the proportional hazards assumption for the sex coefficient, applied inverse probability of censoring weights in CHARLS to mitigate bias from survey attrition, and compared interval-censored models with standard Cox models to accommodate the coarser timing of events between survey waves. Propensity score matching, multiple imputation for missing covariates, E-value analyses to gauge how much unmeasured confounding would be required to overturn the results, and subgroup analyses by socioeconomic status and healthy lifestyle score all supported the robustness of the primary findings. In CHARLS, the researchers even re-derived CKM staging using the China-PAR risk equation as a sensitivity check, further confirming that the observed sex reversal was not an artifact of how the staging algorithm was implemented.

The implications reach well beyond academic curiosity. Clinical risk prediction tools such as PREVENT, SCORE2, and SCORE2-OP, along with China’s own China-PAR equation, already incorporate sex as a risk input, but they are typically calibrated within single populations. The new findings suggest that the magnitude, and even the direction, of the sex coefficient may not transfer cleanly across borders. A risk model trained predominantly on British or European data could systematically miscalculate cardiovascular risk for Chinese women, while models developed in China might understate the danger faced by men in the United Kingdom. For clinicians, this argues for treating sex-specific risk estimates as population-contextual rather than universal constants, and for vigilance in screening patients of the higher-risk sex within each community.

For public health planners, the study underscores the necessity of localized surveillance. Because socioeconomic status and lifestyle behaviors partially mediate the sex differences, interventions that improve economic conditions, reduce smoking, promote healthy diets, and encourage physical activity could narrow the gap in either direction, benefiting the disadvantaged sex in each setting. The authors emphasize that effective cardiovascular prevention may require strategies tailored specifically to males and females within their distinct contexts, a sentiment that aligns with a growing movement in cardiology toward sex-aware precision medicine. The early CKM stages, the study makes clear, are precisely where such tailoring could pay the greatest dividends, before irreversible vascular damage takes hold.

Certain caveats temper the conclusions. Both cohorts are observational, so residual confounding cannot be excluded despite the extensive adjustments. The CHARLS sample is considerably smaller and relies on self-reported and survey-based clinical data, and the stage 3 finding in that cohort was statistically imprecise. CKM staging was operationalized slightly differently in the two studies, reflecting data availability, although the sensitivity analyses suggest this did not drive the divergent results. Nevertheless, the consistency of the sex reversal across stages, models, and sensitivity analyses within each cohort makes the central message hard to dismiss: the relationship between sex and cardiovascular risk in the preclinical CKM spectrum is cohort-specific, shaped by biology and circumstance in equal measure, and any serious effort to curb the global cardiovascular epidemic must confront that complexity head-on.

Subject of Research: Sex differences in cardiovascular disease risk across cardiovascular-kidney-metabolic syndrome stages in two prospective cohorts

Article Title: Sex differences in risk of cardiovascular disease in participants with cardiovascular-kidney-metabolic syndrome stages 0–3: parallel analyses of two prospective cohorts

Article References: Sex differences in risk of cardiovascular disease in participants with cardiovascular-kidney-metabolic syndrome stages 0–3: parallel analyses of two prospective cohorts. (n.d.). https://doi.org/10.1186/s13293-026-00991-w

Image Credits: AI Generated

DOI: 10.1186/s13293-026-00991-w

Keywords: cardiovascular-kidney-metabolic syndrome, cardiovascular disease, sex differences, UK Biobank, CHARLS, CKM stages, risk prediction, public health, cohort study, metabolic syndrome, prevention, epidemiology

The study set out to answer a deceptively simple question: what matters most to patients living with cardiovascular-kidney-metabolic syndrome? To find out, the team conducted semi-structured interviews with 29 eligible patients diagnosed at a tertiary hospital in Hangzhou, Zhejiang Province. Semi-structured interviewing is a qualitative method in which researchers follow a flexible guide of open-ended questions, allowing participants to raise themes the researchers had not anticipated while still ensuring that core topics are covered with everyone. The interviews were then subjected to thematic analysis, a systematic process of coding transcript data and iteratively grouping codes into themes. Importantly, the analysts combined deductive and inductive approaches: deductive coding applied a pre-existing conceptual lens, in this case the World Health Organization’s framework on social determinants of health, while inductive coding allowed new patterns to emerge directly from the patients’ own words. This dual strategy meant the resulting framework was anchored in established theory but not constrained by it.

The choice of the social determinants lens is central to the study’s contribution. Social determinants of health are the non-medical conditions in which people are born, live, work and age, including economic stability, education, social support, neighborhood environment and access to responsive health services. Decades of epidemiological research have shown that these forces often shape health outcomes more powerfully than clinical interventions themselves. For patients juggling heart failure, declining kidney function and metabolic derangement simultaneously, those forces are not abstract; they determine whether a prescribed diet is affordable, whether dialysis appointments can fit around work, and whether a family can absorb the financial shock of a hospitalization. By organizing patient values through this lens, the researchers were able to capture not only what patients want, but the social terrain on which those wants must be pursued.

From the analysis, the team distilled a cardiovascular-kidney-metabolic health values framework comprising ten domains that participants regarded as essential to their health and well-being. These domains were grouped into three value orientations reflecting the social scale at which each operates. Five domains were individual-oriented: preserving physical and cognitive function; psychological well-being and meaning; informed engagement in health management; the quality-longevity trade-off; and financial and insurance security. One domain was interpersonal-oriented: social connectedness and belonging. Two were community-oriented: responsive and coordinated healthcare, and a health-supportive living environment. The structure itself carries a message, since it implies that a patient’s health values cannot be understood, let alone honored, within the walls of a clinic alone.

Several of the individual-oriented domains deserve closer inspection because they challenge conventional assumptions about chronic disease care. The quality-longevity trade-off domain reflects the fact that many patients explicitly weigh length of life against the quality of the years remaining, a calculation that clinicians rarely surface in shared decision-making but that fundamentally changes which treatments feel worthwhile. The financial and insurance security domain highlights how the affordability of medications, monitoring devices and hospital episodes shapes adherence and, ultimately, outcomes; a regimen that is pharmacologically optimal but economically unsustainable is, in practice, not a treatment plan at all. Informed engagement in health management, meanwhile, captures patients’ desire to understand their conditions well enough to participate meaningfully in decisions, rather than to be passive recipients of instructions.

The interpersonal and community-oriented domains extend the framework beyond the individual. Social connectedness and belonging emerged as a value in its own right, consistent with a large body of evidence linking isolation to worse cardiovascular and renal outcomes. The two community-oriented domains, responsive and coordinated healthcare and a health-supportive living environment, speak to structural features of patients’ worlds: whether the health system communicates across its own silos so that cardiology, nephrology and endocrinology do not issue contradictory advice, and whether homes and neighborhoods make healthy behavior physically and socially feasible. For a syndrome whose management depends on daily medication, diet, activity and monitoring, an environment that sabotages those behaviors can nullify even the best-designed care plan.

The authors position the framework as a conceptual and practical basis for eliciting patient-centered values that are often overlooked in routine clinical care. In practical terms, they suggest it could inform the development of conversational aids that help clinicians ask better questions, decision-support tools that surface a patient’s priorities at the point of choice, and personalized care plans that reflect lived experience and social context rather than biomarker trajectories alone. The framework also aligns with emerging models such as Patient Priorities Care, an approach developed in the United States that explicitly identifies and operationalizes what matters most to patients with multiple chronic conditions, and it responds to global calls from bodies including the World Health Organization to advance genuinely patient-centered care.

The study’s methodology was designed to meet rigorous qualitative standards. The authors report following the Consolidated Criteria for Reporting Qualitative Research, the internationally recognized checklist for transparency in qualitative studies, and the research received ethics approval from the Ethics Committee of Sir Run Run Shaw Hospital affiliated with Zhejiang University School of Medicine, with all participants providing written informed consent. Interviews were anonymized, participants could withdraw at any time, and the analysis was conducted in accordance with the Helsinki Declaration and Committee on Publication Ethics guidelines. The work was supported by the Pioneer and Leading Goose R&D Program of Zhejiang, the National Natural Science Foundation of China, the Zhejiang Provincial Natural Science Foundation and several regional funding programs, none of which influenced the design, analysis or reporting.

Like all qualitative research, the study has boundaries that shape how far its conclusions travel. Twenty-nine patients at a single tertiary hospital in eastern China cannot represent every patient with the syndrome worldwide, and values around family obligation, insurance coverage and health system navigation are inevitably colored by cultural and institutional context. The authors themselves frame the framework as a foundation to be tested, refined and adapted rather than a finished prescription. Even so, the core insight travels well: when clinicians ask patients with cardiovascular-kidney-metabolic syndrome what they want, the answers are not simply lower blood pressure or better glucose control, but the ability to think clearly, stay solvent, remain connected to the people they love and live in places that make health possible.

The broader significance of the work lies in its timing. As health systems worldwide confront aging populations and rising multimorbidity, the gap between guideline-driven care and patient-driven care is widening, and frameworks like this one offer a bridge. By giving clinicians and researchers a shared vocabulary of ten concrete value domains, the study makes it easier to build measurement tools, training curricula and digital decision aids that operationalize patient priorities rather than merely praising them in mission statements. If the framework is validated and adopted, the routine conversation at the bedside could shift from what is the matter with this patient to what matters to this patient, a small grammatical change with potentially profound consequences for the millions living at the intersection of heart, kidney and metabolic disease.

Subject of Research: A qualitative study developing a health values framework for patients with cardiovascular-kidney-metabolic syndrome using a social determinants of health perspective.

Article Title: Developing a health values framework for patients with cardiovascular-kidney-metabolic syndrome: a qualitative exploration through the lens of social determinants of health

Article References: Xue, E., Wu, J., Chen, L., Huang, Z., Gao, S., Gao, K., Chen, D., Zhao, B., Wu, Q., Fu, Y., Yu, J., Du, H., Ye, Z., & Shao, J. (2026). Developing a health values framework for patients with cardiovascular-kidney-metabolic syndrome: a qualitative exploration through the lens of social determinants of health. BMC Nursing. https://doi.org/10.1186/s12912-026-05352-x

Image Credits: AI Generated

DOI: 10.1186/s12912-026-05352-x

Keywords: cardiovascular-kidney-metabolic syndrome, patient-centered care, social determinants of health, qualitative research, health values framework, chronic kidney disease, personal values, health priorities, nursing, shared decision-making, multimorbidity, thematic analysis

The study drew on the National Health and Nutrition Examination Survey, or NHANES, covering survey cycles from 2007 to 2018, with mortality outcomes linked to the National Death Index through December 31, 2019. After applying survey weights, the analytic cohort represented approximately 106.9 million US adults, with a mean age of 47.2 years. Rather than relying on body mass index alone, the investigators stratified participants into four distinct body composition phenotypes using two measurements: BMI, which captures overall mass relative to height, and the waist-to-height ratio, which serves as a practical proxy for central or abdominal adiposity. The four groups were obesity with central adiposity, obesity without central adiposity, normal weight with central adiposity, and normal weight without central adiposity.

The distribution of these phenotypes across the American population proved revealing in its own right. A slim majority, 53.3 percent of the weighted cohort, fell into the normal weight without central adiposity category, the presumed metabolically healthy baseline. Another 33.9 percent carried both a high BMI and a high waist-to-height ratio, the classic pattern of generalized obesity. But two smaller and often overlooked groups drew the researchers’ attention: 8.1 percent of adults had normal BMI values but prominent central fat stores, a phenomenon sometimes called normal weight central adiposity, while 4.7 percent were obese by BMI yet lacked significant abdominal fat accumulation. These last two groups complicate the simple arithmetic of conventional obesity screening.

The central outcome of the investigation was cardiovascular-kidney-metabolic multimorbidity, defined as the coexistence of two or more of the following conditions: hypertension, hyperlipidemia, diabetes, chronic kidney disease, or established cardiovascular disease. This clustering of cardiometabolic disorders, increasingly framed under the umbrella of cardiovascular-kidney-metabolic syndrome, has been recognized by the American Heart Association as a major and growing driver of cardiovascular events and death. The syndrome reflects the intimate physiological coupling of the heart, kidneys, and metabolic organs: insulin resistance accelerates atherosclerosis, declining kidney function worsens volume overload and hypertension, and adipose tissue dysfunction amplifies inflammatory signaling that damages vascular beds throughout the body.

When the researchers tabulated multimorbidity prevalence across body composition phenotypes, a clear hierarchy emerged. Normal weight individuals with central adiposity had the highest rate of cardiovascular-kidney-metabolic multimorbidity at 46.5 percent, meaning nearly half of these apparently slim adults already carried at least two of the five defining conditions. This exceeded the multimorbidity burden observed in people with obesity with central adiposity, and it dwarfed the rates seen in the two phenotypes without abdominal fat excess. In other words, the single group that conventional BMI-based screening would most reliably classify as low risk was, by this metric, the sickest.

Mortality analyses sharpened the message considerably. Using survey-weighted Cox proportional hazards models, which allow researchers to estimate the association between a characteristic and the timing of death while adjusting for confounding factors and accounting for the complex sampling design of NHANES, the team found that normal weight adults with central adiposity faced an adjusted hazard ratio of 1.87 for all-cause mortality compared with the reference group, a statistically significant elevation with a 95 percent confidence interval of 1.08 to 3.25 and a p value of 0.025. Even more dramatic was the association with cardiovascular death: the adjusted hazard ratio reached 7.76, with a 95 percent confidence interval of 1.01 to 59.76 and a p value of 0.049. While the wide confidence interval reflects the relatively small number of events in this subgroup and should temper strong causal interpretation, the direction and magnitude of the association are consistent with a substantially elevated cardiovascular risk.

Kaplan-Meier survival curves, a standard technique for visualizing the probability of surviving over time across groups, reinforced the statistical models. Participants who combined cardiovascular-kidney-metabolic multimorbidity with the normal weight central adiposity phenotype demonstrated the poorest long-term survival of any group in the analysis, with the difference between curves reaching statistical significance at p less than 0.001. This convergence of evidence, spanning prevalence estimates, adjusted hazard modeling, and nonparametric survival analysis, points toward a coherent conclusion: the combination of a slim silhouette and a protruding waistline represents a particularly dangerous metabolic signature when it coexists with clustered cardiometabolic disease.

The biological plausibility behind these findings rests on the distinct behavior of visceral adipose tissue compared with subcutaneous fat. Fat deposited around internal organs is not an inert energy reservoir; it is a hormonally and immunologically active tissue that drains directly into the portal circulation, delivering free fatty acids and inflammatory cytokines to the liver and promoting insulin resistance, dyslipidemia, and hepatic steatosis. Visceral fat accumulation is also closely linked to ectopic fat deposition in the liver, pancreas, and heart itself, mechanisms that have been implicated in the progression of metabolic dysfunction-associated steatotic liver disease, type 2 diabetes, and atherosclerotic cardiovascular disease. A person with a normal BMI but a high waist-to-height ratio may therefore harbor a metabolically hostile internal environment that is invisible to weight-based screening, while some individuals with obesity and preserved fat distribution may be relatively protected.

The study arrives at a moment when the scientific community is actively rethinking how obesity itself should be defined. A recent international commission has proposed diagnostic criteria for clinical obesity that move beyond BMI toward measures of fat distribution and organ dysfunction, and prior research has repeatedly shown that waist-to-height ratio outperforms BMI as a screening tool for cardiometabolic risk factors. The new findings extend this literature into the specific arena of cardiovascular-kidney-metabolic multimorbidity and long-term survival in a nationally representative population. The authors conclude that normal weight individuals with central adiposity bear the greatest CKM burden and mortality risk, a result that highlights the limitations of BMI-based risk assessment and argues for incorporating simple anthropometric measures of central fat, such as the waist-to-height ratio, into routine clinical screening. For clinicians, the practical implication is straightforward: a tape measure around the waist may identify high-risk patients that the scale alone would miss, and for the public, the reassuring sight of a normal number on the bathroom scale should not be mistaken for a clean bill of cardiometabolic health.

Subject of Research: The association of body composition phenotypes with cardiovascular-kidney-metabolic multimorbidity and long-term mortality in a US population-based cohort

Article Title: Body composition phenotypes are key predictors of cardiovascular-kidney-metabolic multimorbidity and long-term mortality: insights from a population-based cohort study

Article References: Kong, G., Intaran, M. A. U., Soh, E. S. W., Yazicioglu, Y., Goh, R., Nagarajan, S., Wang, J.-W., Zhou, X., Zhou, X.-D., Zheng, M.-H., Chan, M. Y., Mehta, A., le Roux, C. W., Mamas, M. A., Khan, M. S., & Chew, N. W. S. (2026). Body composition phenotypes are key predictors of cardiovascular-kidney-metabolic multimorbidity and long-term mortality: insights from a population-based cohort study. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03010-5

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03010-5

Keywords: cardiovascular-kidney-metabolic syndrome, central adiposity, body mass index, waist-to-height ratio, obesity, NHANES, multimorbidity, mortality, visceral fat, cardiometabolic risk, population-based cohort study, risk screening

CKM syndrome is a framework developed to describe the biological links among obesity, diabetes, high blood pressure, cardiovascular disease and chronic kidney disease. Rather than treating these conditions as isolated problems, the framework views them as interconnected consequences of metabolic stress, vascular damage, inflammation and declining organ function. In the operational classification used by the researchers, stages 2–3 encompass people with metabolic risk factors, kidney abnormalities or subclinical cardiovascular disease, while stage 4 represents established cardiovascular disease, kidney disease or both in the presence of metabolic risk. This distinction matters because patients with advanced CKM syndrome often have a high risk of hospitalization, progressive loss of kidney function and death, while also being more difficult to include in conventional trials. By mapping existing trial populations onto CKM stages, the investigators sought to test whether the benefits of SGLT2 inhibition extended across this clinically connected spectrum.

SGLT2 inhibitors were first developed as glucose-lowering medicines for type 2 diabetes, but their effects extend beyond blood sugar control. The drugs block the SGLT2 protein in the proximal tubule of the kidney, where much of the glucose and sodium filtered from the blood is normally reclaimed. Inhibition increases urinary glucose excretion and causes a modest increase in sodium loss. That change alters signaling between the kidney’s filtration apparatus and the renin–angiotensin system, helping to reduce pressure inside the glomeruli, the microscopic structures that filter blood. The medicines also produce a mild diuretic and natriuretic effect, reducing fluid congestion that can strain the heart. Researchers believe these mechanisms, together with changes in renal oxygen demand, vascular function and cardiac metabolism, help explain why the drugs can benefit patients with or without diabetes.

Sun, Guo and their colleagues searched PubMed/MEDLINE, Web of Science, Embase and the Cochrane Central Register of Controlled Trials for randomized controlled trials available through 25 February 2026. They included trials comparing an SGLT2 inhibitor with placebo or usual care and grouped trial populations, or mutually exclusive subgroups reported within trials, according to the CKM stage framework. Nineteen reports derived from 11 parent randomized trials met the criteria. A total of 18,547 participants were assigned to the CKM stages 2–3 group, while 54,673 were classified as stage 4. The researchers pooled six time-to-event outcomes using restricted maximum likelihood random-effects models. This statistical approach allows for the possibility that the true treatment effect differs somewhat among studies rather than assuming that all trials are estimating one identical effect.

The clearest signals involved heart failure and kidney disease. For the composite heart-failure outcome, the hazard ratio was 0.80 in CKM stages 2–3, with a 95 percent confidence interval of 0.68 to 0.93, and 0.77 in stage 4, with a confidence interval of 0.73 to 0.81. A hazard ratio below 1 indicates fewer events in the SGLT2 inhibitor group; these estimates correspond roughly to relative reductions of 20 percent and 23 percent, respectively. For hospitalization for heart failure, the hazard ratio was 0.61 in stages 2–3 and 0.71 in stage 4, equivalent to approximate relative reductions of 39 percent and 29 percent. Kidney outcomes also favored treatment, with hazard ratios of 0.61 and 0.64 in the two groups. These findings are consistent with the drugs’ established ability to slow clinically important kidney deterioration and reduce heart-failure events in several different patient populations.

The statistical comparisons did not show that the apparent differences between groups were significant. The P value for the comparison of composite heart-failure outcomes between CKM stages 2–3 and stage 4 was 0.65. For heart-failure hospitalization it was 0.24, and for kidney outcomes it was 0.64. In practical terms, the available data did not demonstrate that one CKM group gained more or less benefit than the other. But a non-significant difference is not the same as proof of identical effects. The stages 2–3 analysis was based on only four estimates, creating wider confidence intervals and greater uncertainty. Stage 4 estimates were generally more precise because the group included more participants and more events. The researchers therefore describe the results as evidence of benefit in both groups, not as definitive evidence that the magnitude of benefit is equivalent.

The analysis also examined major adverse cardiovascular events, commonly known as MACE, and all-cause mortality. Estimates for MACE and mortality in CKM stage 4 were more precise, reflecting the larger evidence base in that category, but the source material does not report a single statistically significant stage-based difference for these outcomes. The researchers registered five main outcomes rather than designating one primary endpoint, while all-cause mortality was registered as a secondary outcome. That distinction is important because a study evaluating several outcomes can produce a complex pattern of results, and individual findings may vary in certainty. An exploratory Egger test for all-cause mortality produced a P value of 0.025, raising the possibility of small-study effects or publication bias. Such tests are difficult to interpret when the number of contributing estimates is limited, so the result is a warning signal rather than evidence that the overall mortality conclusion is invalid.

To test whether the findings depended on particular analytical decisions, the investigators performed prespecified sensitivity analyses. They examined alternative statistical models, removed the SOLOIST-WHF trial because a selected efficacy result was judged to have a high risk of bias, tested different definitions of kidney endpoints and assessed whether any single study disproportionately influenced the results. They also investigated possible small-study effects. The principal heart-failure and kidney findings remained stable across these checks, strengthening confidence that the observed pattern was not created by one trial or one endpoint definition. Nevertheless, meta-analysis inherits limitations from the studies it combines. Trial participants may differ in baseline kidney function, diabetes status, heart-failure phenotype, medication use and follow-up duration, while operationally assigning populations to CKM stages cannot fully reproduce the complexity of individual patients.

The findings arrive as SGLT2 inhibitors are increasingly used across cardiology, nephrology and endocrinology, including in patients with heart failure with reduced, mildly reduced or preserved ejection fraction and in people with chronic kidney disease. Their apparent benefits across these specialties have helped shift the drugs from narrowly targeted diabetes treatments to therapies with broader cardiorenal applications. The new review reinforces that cross-disciplinary picture: patients at different points along the CKM pathway experienced fewer heart-failure and kidney events when receiving an SGLT2 inhibitor than when receiving placebo or usual care. Still, treatment decisions must account for kidney function, volume status, genital and urinary infections, ketoacidosis risk and other individual factors. The authors’ central conclusion is appropriately cautious: SGLT2 inhibitors favored heart-failure and kidney outcomes in both CKM stage groups, but more evidence—especially in earlier-stage CKM disease—is needed to determine how treatment effects compare across the full continuum.

Subject of Research: Cardiorenal effects of SGLT2 inhibitors across cardiovascular-kidney-metabolic syndrome stages 2–3 and stage 4

Article Title: SGLT2 inhibitors and cardiorenal outcomes across operationally mapped cardiovascular-kidney-metabolic syndrome stages 2–3 and stage 4: a systematic review and meta-analysis

Article References: Sun, S., Guo, Y., Wu, H. et al. SGLT2 inhibitors and cardiorenal outcomes across operationally mapped cardiovascular-kidney-metabolic syndrome stages 2–3 and stage 4: a systematic review and meta-analysis. BMC Endocrine Disorders (2026). Original research article

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02478-6

Keywords: SGLT2 inhibitors, cardiovascular-kidney-metabolic syndrome, heart failure, chronic kidney disease, cardiorenal outcomes, randomized controlled trials, systematic review, meta-analysis

Researchers analyzed health data from 1,283 participants enrolled in the Future of Families–Cardiovascular Health Among Young Adults, or FF-CHAYA, study. The cohort was intentionally diverse and included many individuals from socially and economically disadvantaged backgrounds. Investigators evaluated each participant using two complementary frameworks: the American Heart Association’s CKM syndrome staging system and its Life’s Essential 8 cardiovascular health score. They also used ultrasound imaging to examine the carotid arteries, the major blood vessels in the neck that supply blood to the brain. Changes in these arteries can provide an early window into vascular injury long before symptoms develop.

CKM syndrome is staged from 0 to 4 according to a person’s accumulation of risk factors and disease. Stage 0 indicates no identifiable CKM risk factors, while stages 1 through 3 reflect progressively greater abnormalities involving adiposity, glucose regulation, blood pressure, blood lipids, kidney function or subclinical cardiovascular disease. Stage 4 represents established cardiovascular disease, such as coronary heart disease, heart failure or stroke. In this young cohort, about 21% of participants were classified as stage 0, while nearly 80% met the criteria for stages 1, 2 or 3. None had reached stage 4.

The researchers found a clear relationship between more advanced CKM staging and early structural changes in the carotid arteries. Participants in the higher stages tended to have thicker carotid artery walls, a measurement known as carotid intima-media thickness. This thickening is considered an early marker of atherosclerosis, the gradual process in which cholesterol-rich plaques and inflammatory tissue accumulate within artery walls. Although increased carotid wall thickness does not mean that a person has an obstructed artery or will necessarily develop cardiovascular disease, it indicates that vascular biology may already be shifting toward greater stiffness, inflammation and plaque formation.

The association was especially striking because the participants were in their early 20s, an age when cardiovascular disease is often viewed as a distant concern. Arterial injury is usually detected after years of exposure to high blood pressure, unhealthy cholesterol levels, elevated blood sugar, smoking, excess body weight or impaired kidney function. The study indicates that these factors can combine early in adulthood, potentially accelerating damage before traditional clinical risk calculators identify a meaningful short-term threat. The findings therefore challenge the assumption that a young age alone protects people from the earliest stages of cardiovascular decline.

Participants with more advanced CKM syndrome also had lower scores on Life’s Essential 8, the American Heart Association framework for assessing cardiovascular health. The tool measures eight behaviors and health factors: diet, physical activity, tobacco exposure, sleep, body weight, cholesterol, blood glucose and blood pressure. Rather than producing a diagnosis, the score provides a broad assessment of how closely a person’s current health aligns with habits and biological measures associated with lower cardiovascular risk. In the study, lower scores generally accompanied more advanced CKM stages, reinforcing the idea that daily behaviors and measurable metabolic changes are closely connected.

Donald Lloyd-Jones, a study author, said the two approaches should be viewed as complementary rather than competing systems. CKM staging identifies the combination and severity of metabolic, kidney and cardiovascular risk, while Life’s Essential 8 offers practical targets that can be monitored and improved. Together, they may help clinicians recognize young adults who are beginning to accumulate risk even when they have no symptoms. For people in their 20s, the emphasis is not necessarily on predicting an imminent heart attack, but on identifying unfavorable trends and changing them before arterial injury becomes more advanced or irreversible.

Current American Heart Association and American College of Cardiology guidance recommends the PREVENT equations to estimate a person’s 10-year and 30-year risk of cardiovascular disease. However, those equations were developed and validated for adults between 30 and 79 years old, meaning they cannot be reliably applied to the participants in this study. In younger adults, the absence of a high calculated short-term risk may be misleading because age strongly influences the result. A 23-year-old can have obesity, elevated blood pressure, abnormal cholesterol or high blood sugar while still receiving a low near-term risk estimate. Monitoring Life’s Essential 8 measures may therefore provide a more useful starting point for prevention during this stage of life.

The researchers caution that the study cannot prove that CKM syndrome directly caused the arterial changes. Its cross-sectional design captured health status at one point in time, so it cannot establish whether the risk factors preceded the vascular injury or determine how the findings will affect future cardiovascular events. Several outcomes were also examined simultaneously, and some health behaviors were self-reported. Because the cohort included a substantial number of people from disadvantaged backgrounds, the results may not apply equally to every young adult population. Even so, the findings offer a powerful warning: cardiovascular prevention may need to begin well before middle age, when changes in weight, blood pressure, cholesterol, glucose, sleep, physical activity and tobacco exposure can still alter the trajectory of heart, kidney and metabolic health.

Subject of Research: Cardiovascular-kidney-metabolic syndrome, cardiovascular health and early arterial injury in young adults

Article Title: Association between Cardiovascular-Kidney-Metabolic Health and Early Arterial Injury in Young Adults in the United States: The Future of Families – Cardiovascular Health Among Young Adults Study

News Publication Date: Aug. 20, 2026

Web References: American Heart Association CKM syndrome information: https://www.heart.org/en/health-topics/cardiovascular-kidney-metabolic-syndrome/what-is-ckm-health; Life’s Essential 8: https://www.heart.org/en/healthy-living/healthy-lifestyle/lifes-essential-8; American Heart Association newsroom: https://newsroom.heart.org/news/study-found-artery-damage-in-adults-in-their-20s-highlighting-need-for-early-cardiovascular-risk-assessment

References: DOI: 10.1161/CIRCOUTCOMES.125.013042

Keywords: cardiovascular-kidney-metabolic syndrome, CKM syndrome, young adults, arterial injury, carotid artery, atherosclerosis, cardiovascular health, Life’s Essential 8, obesity, diabetes, kidney disease, blood pressure, cholesterol, prevention

CKM syndrome is alarmingly prevalent, with nearly nine out of ten adults in the United States exhibiting at least one condition encompassed by the syndrome. These conditions include hypertension, dyslipidemia characterized by abnormal cholesterol and lipid profiles, elevated blood glucose, compromised renal function, and excess adiposity. The guideline emphasizes that obesity, particularly the accumulation of visceral fat within the abdomen, is a major driver of metabolic dysregulation that accelerates the deterioration of cardiovascular and kidney health.

This syndrome was officially defined by the American Heart Association in 2023, and its recognition facilitates a more integrated approach to diagnosis and management. In essence, individuals with one component of CKM syndrome—such as diabetes or chronic kidney disease—are at significantly elevated risk for the other conditions, with obesity further amplifying this risk. This interconnectedness calls for clinicians to transcend traditional treatment silos and strategize a coordinated approach to patient care.

The guideline notably shifts the conversation about weight from a focus on aesthetics to one centered on metabolic health and disease prevention. Dr. Chiadi E. Ndumele, chair of the guideline writing committee and director of obesity and cardiometabolic research at Johns Hopkins University, articulates that weight is not merely a numerical value on a scale but rather a reflection of how adipose tissue alters metabolic pathways. The distribution and function of fat, particularly in the abdomen, is critical, influencing insulin resistance, inflammatory processes, and vascular health.

Subclinical inflammation induced by visceral adiposity leads to endothelial dysfunction—a precursor to atherosclerosis and vascular stiffness. This dysregulation in vascular tone affects blood pressure control and organ perfusion, setting off a cascade of deteriorative events in both heart and kidney function. The guideline describes this cascade as a rope holding together multiple chronic pathologies, with fat-induced inflammation loosening the fibers.

One of the significant clinical challenges that the guideline confronts is the fragmentation of care. Specialists often treat cardiovascular disease, metabolic disorders, or kidney disease in isolation, inadvertently neglecting the multisystem nature of CKM syndrome. Dr. Fatima Rodriguez of Stanford University highlights the importance of dismantling these silos to recognize the holistic nature of an individual’s disease burden. Incorporating navigators or care coordinators within the healthcare infrastructure is a recommended strategy to facilitate communication among providers and ensure cohesive care plans.

Understanding the pathophysiology of CKM syndrome directs attention to early intervention strategies. The guideline urges health professionals to initiate prevention-focused conversations about weight management far earlier in the clinical course. This proactive stance is designed to intervene before irreversible organ damage occurs, thereby halting or even reversing the syndrome’s progression. It emphasizes that metabolic health can improve irrespective of baseline body mass index if appropriate interventions are undertaken.

The imaging and diagnostic tools recommended include refined methods to assess not only body mass but fat distribution and metabolic markers. Clinicians are encouraged to engage in non-judgmental dialogue that prompts patients to reflect on how their weight may influence blood sugar dynamics, lipid profiles, and renal function. By drawing analogies such as comparing blood vessels to plumbing systems susceptible to “rust” from inflammation, clinicians can render complex pathophysiological mechanisms accessible to patients.

Therapeutic management embraces a multipronged approach. Lifestyle modifications centering on nutrition, physical activity, and behavioral health are foundational pillars. However, pharmacological advances are now integral, with medications like SGLT2 inhibitors and GLP-1 receptor agonists demonstrating efficacy across cardiovascular, metabolic, and renal domains. Additionally, nonsteroidal mineralocorticoid receptor antagonists have emerged as critical agents in mitigating inflammation and fibrosis, thereby protecting organ function.

Data underscores the gravity of obesity-related risk in CKM syndrome, with statistics revealing a 21% increased risk of heart disease and a 32% higher risk of stroke among individuals with excess weight. An incremental 5-unit rise in BMI correlates with a staggering 41% elevation in heart failure risk. These figures echo the urgent necessity for early, individualized intervention strategies that the guideline advocates.

The CKM Health Initiative, launched by the American Heart Association in 2024, complements this guideline by offering a structured path forward for diagnostics, treatment, and education. It aims to empower patients, support communities, and furnish healthcare providers with resources to confront this multifaceted syndrome comprehensively. Through this synergy of research, practice, and policy, the initiative seeks to stem the rising tide of CKM syndrome and its costly implications for public health.

Considerations of social determinants of health are profoundly embedded within the guideline’s framework. Barriers such as socioeconomic constraints, limited access to nutritious foods, and inadequate healthcare resources are acknowledged as obstacles in managing CKM syndrome. Integration of social support mechanisms and patient-centered care models is presented as essential for overcoming these barriers and optimizing health outcomes.

Ultimately, the guideline represents a seismic shift in the management of a previously fragmented constellation of diseases. By framing cardiovascular, kidney, and metabolic conditions as interdependent rather than isolated phenomena, it paves the way for a holistic, precision medicine approach. This paradigm serves not only to improve quality of life and reduce mortality but to alleviate the long-term economic burdens borne by healthcare systems worldwide.

Subject of Research: Cardiovascular-Kidney-Metabolic (CKM) Syndrome, Obesity, Metabolic Health, Integrated Disease Management

Article Title: Breaking New Ground: The First Clinical Guideline for Cardiovascular-Kidney-Metabolic Syndrome

News Publication Date: June 9, 2026

Web References:

• American Heart Association CKM Syndrome
• Circulation Journal Manuscript
• AHA Science News for Professionals

Keywords: Cardiovascular disease, CKM syndrome, obesity, metabolic health, kidney disease, diabetes, visceral fat, inflammation, SGLT2 inhibitors, GLP-1 therapies, integrated care, prevention

At the core of this study is the challenge posed by cardiovascular-kidney-metabolic syndrome—a multifaceted ailment characterized by the synergistic deterioration of heart, renal, and metabolic functions. Traditional therapies often fall short due to systemic side effects or limited efficacy, particularly when therapeutic targets are diffused across multiple organs and pathways. Addressing this gap, the research team engineered a nanocarrier system with the unique ability to detect elevated urea concentrations, a biomarker commonly associated with kidney dysfunction, enabling targeted drug release directly at the site of pathological relevance.

SGLT2 inhibitors have garnered significant attention due to their role in reducing glucose reabsorption in the renal proximal tubules, thereby lowering blood glucose levels and imparting cardio-renal protective effects. However, conventional SGLT2 inhibitors are administered systemically, which can lead to off-target effects and suboptimal drug concentrations at the site of action. By leveraging a nanocarrier that responds to urea levels—a reflection of renal stress—the researchers harnessed a biologically triggered mechanism to localize SGLT2 inhibition precisely where it is most needed.

This nanocarrier strategy hinges on its molecular architecture, where the presence of elevated urea induces conformational changes that trigger drug release. The design incorporates biocompatible materials optimized for circulation stability and controlled activation. This meticulous engineering ensures that the nanocarrier remains inert in healthy tissues but becomes highly active within urea-rich environments, mitigating systemic exposure and potential side effects. Furthermore, the selective release mechanism amplifies therapeutic efficacy by maximizing drug concentration at compromised renal sites without flooding the systemic circulation.

To validate their concept, the research team employed a comprehensive suite of in vitro and in vivo experiments, demonstrating the nanocarrier’s stability, biocompatibility, and site-specific activation. Laboratory assays confirmed an enhanced drug release profile correlated with physiologically relevant urea concentrations, while animal models of cardiovascular-kidney-metabolic syndrome showed marked improvements in metabolic parameters and organ function. These findings suggest that the nanocarrier not only improves glycemic control but also attenuates the progression of organ damage through localized SGLT2 inhibition.

One of the most compelling dimensions of this study is its potential to unravel the intricate crosstalk among metabolic, cardiovascular, and renal pathways. By delivering therapeutics directly to sites burdened by uremic toxins, the nanocarrier disrupts the vicious cycle of metabolic dysregulation and organ dysfunction. This precision medicine approach could recalibrate the treatment paradigms, shifting from broad systemic interventions to sharply targeted therapies that acknowledge and exploit underlying pathophysiological signals.

Importantly, the implications of this research extend beyond the immediate therapeutic applications. The principle of leveraging endogenous metabolic biomarkers, such as urea, to trigger nanocarrier activation heralds a new era in nanomedicine. This modality could be adapted to various disease contexts where local biochemical milieus differ significantly from systemic environments, enabling a customizable platform for diverse clinical challenges.

The researchers also addressed potential concerns regarding nanocarrier safety and immunogenicity, presenting data that underscore the absence of acute toxicity or adverse immune responses over extended treatment durations. This aspect is crucial for clinical translation, as safety and tolerability remain critical hurdles in nanotechnology-based therapies. The study’s rigorous approach to biocompatibility and pharmacokinetics highlights a robust pathway toward eventual human trials.

In addition to metabolic rescue, the targeted SGLT2 inhibition by the nanocarrier induced favorable hemodynamic changes and improved mitochondrial function within affected tissues. This multifaceted therapeutic impact highlights the intertwined nature of metabolic and organ-specific disruptions and underscores the nanocarrier’s capacity to effect systemic improvements by acting locally. Such findings pave the way for broad implications in managing not only diabetes-related complications but also complex syndromes that defy traditional therapeutic silos.

The publication of this study in a high-impact journal like Nature Communications accentuates the scientific community’s recognition of its transformative potential. Peer reviewers and experts applaud the integration of chemical engineering, molecular biology, and clinical insight that underpin this breakthrough. The cross-disciplinary synergy sets a precedent for future endeavors seeking to tackle similarly challenging multisystem diseases through innovative drug delivery systems.

Looking ahead, the research team envisions refining the nanocarrier platform to enhance specificity and scalability, with ongoing efforts to incorporate additional biomarkers and therapeutic agents. The adaptability of this technology offers exciting prospects for personalized medicine, where patient-specific metabolic profiles guide the deployment of tailored nanotherapies. Such advances could usher in a new standard of care that optimizes efficacy while minimizing risks.

Moreover, the alignment of this nanocarrier with current clinical practices for managing diabetes and kidney disease could facilitate its integration into existing treatment regimens. By complementing or even replacing systemic SGLT2 inhibitors, the urea-activated system has the potential to improve patient adherence and reduce complications, ultimately enhancing quality of life. The prospect of reducing cardiovascular and renal morbidity through a single targeted intervention is particularly appealing amid the rising global burden of metabolic disorders.

The broader biomedical field stands to gain from the methodological innovations demonstrated in this study. The rational design of stimuli-responsive nanocarriers attuned to disease-specific biochemical signatures represents a paradigm shift in drug delivery science. This strategy emphasizes precision, temporal control, and minimization of collateral effects—criteria increasingly recognized as essential for next-generation therapeutics.

In conclusion, the unveiling of a urea-activated nanocarrier for site-specific SGLT2 inhibition marks a significant milestone in the quest to conquer the devastating triad of cardiovascular, kidney, and metabolic diseases. By fusing molecular sensing with controlled drug delivery, Ren and colleagues have charted a compelling pathway toward therapies that are both smarter and safer. The anticipated ripple effects of this research promise to invigorate the fields of nanomedicine, metabolic disease treatment, and beyond, inspiring novel approaches that harness the intimate dialogue between pathological signals and engineered nanotechnologies.

Subject of Research: Development of a urea-activated nanocarrier for targeted SGLT2 inhibition and metabolic rescue in cardiovascular-kidney-metabolic syndrome.

Article Title: A urea-activated nanocarrier for site-specific SGLT2 inhibition and metabolic rescue against cardiovascular-kidney-metabolic syndrome.

Article References:
Ren, X., Gao, D., Yun, R. et al. A urea-activated nanocarrier for site-specific SGLT2 inhibition and metabolic rescue against cardiovascular-kidney-metabolic syndrome. Nat Commun (2026). https://doi.org/10.1038/s41467-026-71424-w

Image Credits: AI Generated